# A Study of LY2875358 in Japanese Participants With Advanced Cancer

> **NCT01602289** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 17 (actual)

## Conditions studied

- Solid Tumors
- Lymphoma
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** LY2875358
- **DRUG:** Erlotinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01602289
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602289, "A Study of LY2875358 in Japanese Participants With Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01602289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*